ArticleTransplantation direct2025
External Validation of an Easy-to-Use, Adjustable Score for Short- to Long-term Prediction of Kidney Graft Failure.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many tools have been developed to estimate the risk of graft loss for kidney transplant patients, but only a few have been thoroughly validated. Methods: We previously developed the adjustable graft failure score (AdGFS), an easy-to-use tool combining 2-7 variables routinely collected at 1 y posttransplant in all of the transplantation centers. During model development, we selected the variables using random survival forest, a machine learning method, to come up with a simple decision tree based on: donor age; pretransplant non-donor-specific anti-HLA antibodies (presence/absence); kinetic profile of serum creatinine using its values at months 1, 3, 6, and 12 posttransplant; serum creatinine and proteinuria (g/L or g/24 h) at 1 y posttransplantation; occurrence of de novo donor-specific anti-HLA antibodies (yes/no); occurrence of a first episode of acute rejection. The aim of the present study was to validate AdGFS on 2 large, independent, longitudinal cohorts of kidney transplant patients from Leuven, Belgium (n = 930 patients) and Lyon, France (n = 307 patients). Results: The 4 risk groups obtained actually showed very large and significant differences in graft survival at 10 y posttransplantation: 89%, 81%, 59%, and 23% in the low, intermediate, high, and very high-risk groups, respectively. At 2, 5, and 10 y posttransplantation, the area under the curve (95% confidence interval) of the receiver operating characteristic curve of AdGFS was 0.86 (0.76-0.96), 0.76 (0.70-0.82), and 0.73 (0.69-0.77), respectively. Conclusions: This external validation study confirmed that AdGFS is clinically applicable for the long-term risk graduation of graft loss at the first transplantation anniversary. It suggests that it may be used to tailor the overall management of the patient to the individual risk and as a surrogate outcome in clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.